@xconomy.com 4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com 4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com 4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com 5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com 5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M